DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$10.73
+0.42 (+4.07%)
Open$10.41
Previous Close$10.31
Day High$10.97
Day Low$10.41
52W High$11.23
52W Low$2.60
Volume—
Avg Volume339.0K
Market Cap632.76M
P/E Ratio—
EPS$-1.22
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+449.4% upside
Current
$10.73
$10.73
Target
$58.95
$58.95
$40.84
$58.95 avg
$77.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 133.74M | 128.39M | 127.15M |
| Net Income | -5,858,142 | -5,637,576 | -5,243,986 |
| Profit Margin | -4.4% | -4.4% | -4.1% |
| EBITDA | -5,607,781 | -6,075,682 | -5,861,844 |
| Free Cash Flow | -4,251,021 | -4,814,286 | -3,496,781 |
| Rev Growth | +7.4% | +3.0% | +5.7% |
| Debt/Equity | 0.91 | 1.04 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |